This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Vifor Pharma Ltd.
Vifor Pharma Ltd., a leading global pharmaceutical company headquartered in Switzerland (CH), specialises in iron deficiency and nephrology. Founded in 2000, Vifor Pharma has established itself as a key player in the industry, focusing on innovative therapies that address critical health needs. The company operates extensively across Europe, North America, and Asia, delivering high-quality products that enhance patient outcomes. Vifor Pharma's core offerings include intravenous iron therapies and treatments for chronic kidney disease, distinguished by their efficacy and safety profiles. The company has achieved notable milestones, including strategic partnerships and a robust pipeline of products that cater to underserved patient populations. With a strong market position, Vifor Pharma continues to drive advancements in the pharmaceutical sector, committed to improving the lives of patients worldwide.
DitchCarbon Score
How does Vifor Pharma Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vifor Pharma Ltd.'s score of 49 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vifor Pharma Ltd., headquartered in Switzerland (CH), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of CSL Limited, which influences its climate commitments and reporting practices. Vifor Pharma's climate initiatives and reduction targets are inherited from CSL Limited, which operates at a cascade level of 2. However, there are no documented reduction targets or specific climate pledges available for Vifor Pharma at this time. As part of the broader industry context, Vifor Pharma is expected to align with the sustainability and climate strategies of its parent company, CSL Limited, which may include participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). In summary, while Vifor Pharma Ltd. does not currently provide specific emissions data or reduction targets, it is positioned within a corporate structure that prioritises climate commitments through its parent company, CSL Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vifor Pharma Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
